(Q46819255)

English

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

scientific article published in February 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16307018

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity (English)

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16307018

Isaac Ben-Bassat

7

object named as

Ben-Bassat I

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16307018

author name string

Shimoni A

1

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16307018

Hardan I

2

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16307018

Shem-Tov N

3

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16307018

Yeshurun M

4

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16307018

Yerushalmi R

5

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16307018

Avigdor A

6

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16307018

Nagler A

8

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16307018

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 February 2006

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16307018

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16307018

20

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16307018

322-328

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16307018

2

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16307018

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404037

0 references

Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

21 January 2018

Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

21 January 2018

Clinical implications of minimal residual disease monitoring for stem cell transplantation after reduced intensity and nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

21 January 2018

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

21 January 2018

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

21 January 2018

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

21 January 2018

Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

21 January 2018

Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

21 January 2018

Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

21 January 2018

Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

21 January 2018

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

21 January 2018

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

21 January 2018

Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

21 January 2018

Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

21 January 2018

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

21 January 2018

The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

21 January 2018

How does bone-marrow transplantation cure leukaemia?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

7 January 2021

based on heuristic

inferred from DOI database lookup

Venoocclusive disease of the liver following bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

7 January 2021

based on heuristic

inferred from DOI database lookup

Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

7 January 2021

based on heuristic

inferred from DOI database lookup

Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia in first complete remission: new answers for an old question

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404037

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2404037

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16307018

release_oxs3pcciynasrgjdmqbhbl2xs4

1 reference

https://api.fatcat.wiki/v0/release/oxs3pcciynasrgjdmqbhbl2xs4

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16307018

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46819255&oldid=2133427012"